Patents by Inventor Maud JOST
Maud JOST has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896602Abstract: The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or in combination with progestogenic components, and this to an extent surpassing the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.Type: GrantFiled: September 30, 2022Date of Patent: February 13, 2024Assignee: ESTETRA SRLInventors: Maud Jost, Glwadys Rausin
-
Publication number: 20230248743Abstract: Described are methods of providing contraception in a woman having a BMI?30.0 kg/m2, comprising: selecting a woman determined to have a BMI?30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI?30.0 kg/m2, comprising: selecting a woman determined to have a BMI?30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.Type: ApplicationFiled: February 9, 2023Publication date: August 10, 2023Applicant: ESTETRA SRLInventors: Jean-Michel FOIDART, Maud JOST
-
Patent number: 11666585Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: GrantFiled: October 11, 2022Date of Patent: June 6, 2023Assignee: ESTETRA SRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20230073911Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: October 24, 2022Publication date: March 9, 2023Applicant: ESTETRA SRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20230050253Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: October 11, 2022Publication date: February 16, 2023Applicant: ESTETRA SPRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20230041304Abstract: The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or in combination with progestogenic components, and this to an extent surpassing the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.Type: ApplicationFiled: September 30, 2022Publication date: February 9, 2023Applicant: ESTETRA SRLInventors: Maud JOST, Glwadys RAUSIN
-
Publication number: 20230031329Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: August 23, 2022Publication date: February 2, 2023Applicant: ESTETRA SRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20230025785Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: August 31, 2022Publication date: January 26, 2023Applicant: ESTETRA SRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Patent number: 11484539Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: GrantFiled: April 19, 2019Date of Patent: November 1, 2022Assignee: Estetra SPRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Patent number: 11452733Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: GrantFiled: April 19, 2019Date of Patent: September 27, 2022Assignee: Estetra SPRLInventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20210154212Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: April 19, 2019Publication date: May 27, 2021Inventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20210154211Abstract: The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.Type: ApplicationFiled: April 19, 2019Publication date: May 27, 2021Inventors: Melanie Taziaux, Glwadys Rausin, Maud Jost, Marie Mawet
-
Publication number: 20200046729Abstract: Described are combined oral contraceptive compositions with reduced cardiovascular effects and methods using them. In some embodiments, the methods relate to contraceptive methods or methods for treating dysmenorrhea with reduced cardiovascular effects, such as reduced venous thromboembolism (VTE) risk. The methods comprise administering to a female subject an effective amount of an estetrol component and a progestogenic component. The methods enjoy a favourable profile for thromboembolism compared to currently available methods which employs contraceptives from the so-called second, third or fourth generation.Type: ApplicationFiled: September 17, 2019Publication date: February 13, 2020Applicant: ESTETRA SPRLInventors: Maud JOST, Glwadys RAUSIN
-
Publication number: 20190167700Abstract: The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or in combination with progestogenic components, and this to an extent surpassing the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.Type: ApplicationFiled: August 7, 2017Publication date: June 6, 2019Applicant: ESTETRA SPRLInventors: Maud JOST, Glwadys RAUSIN